Lupus Market Analysis

Global Lupus Market Overview

Lupus Market Size was valued at USD 3.3 billion in 2022 and is projected to grow from USD 3.6 Billion in 2023 to USD 6.78 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.3% during the forecast period (2023 - 2032). 

Rising awareness and healthcare expenses, growing female population, quick urbanization, favorable Government initiatives, and increasing prevalence of SLE disease are just a few of the market drivers that are boosting the market.

Source: Secondary Research, MRFR Database, Primary Research, and Analyst Review

Lupus Market Trends

• 
  

  Factors fueling the market growth of the lupus market

  
  

The increasing prevalence of cutaneous lupus erythematosus is a main driver for this market's growth, another significant factor influencing the growth of the lupus market is the increasing healthcare expenditure which helps in bettering its infrastructure. Further, progressive initiatives by private and public organizations to spread the word about it will expand the cutaneous lupus erythematosus market. In addition, the high demand for effective therapies will enlarge the cutaneous lupus erythematosus market. Nonetheless, the market's growth is fueled by the rising number of R&D activities. This will give advanced opportunities for the lupus market growth. 

Together with this, increasing drug permits and launches will further propel the market's growth rate. Moreover, rising investment in the development of improved technologies and an increase in the number of enhancing markets will further provide beneficial opportunities for the lupus erythematosus market growth during the study period. Thus, this factor will fuel the market CAGR.

SLE disease type of Lupus is mostly found among the women population, various organizations and the government is taking initiatives to make people aware, and with government support, various research institutes are providing drugs and therapies andeisE patients. Several new drugs are under trial, which are funded by the government. The Centers in the US for Disease Control and Prevention (CDC) is regularly releasing SLE disease statistics to let the citizens know about the consequences.

However, the market has been facing some challenges, mainly a rigid regulatory environment, the high cost of the development of drugs, etc. Stringent regulations are one of the important challenges to the systemic lupus erythematosus (SLE) market. Generally, medical gadgets, all vaccinations, and helpful medications made to treat certain diseases have gone through extensive testing in clinical trials to ensure their safety and feasibility in treating the disease. 

These trials are very time-consuming, and the rules and regulations associated with them are very strict. Owing to this reason, pharmaceutical companies or research organizations have to experience slow progress toward regulatory approvals. 

The strict regulations would restrain the growth of the market, but there is also high research and development (R&D) activity for the development of new therapies for Lupus, with more than three monoclonal antibodies (mAB)-based therapies that could potentially enter the SLE and LN market during the forecast window from 2023 to 2031; thus, it is anticipated that this aspect will accelerate Lupus market revenue ly.

Lupus Market Segment Insights

Lupus Type Insights

The  lupus market segmentation, based on types, includes systemic lupus erythematosus, neonatal Lupus, and others. The systemic lupus erythematosus segment is expected to hold the largest market share according to  lupus market data owing to the increasing prevalence and high drug development in coming years. SLE is a complex, chronic, multifactorial, autoimmune disorder that involves multiple organ systems, including the skin, heart, joints, blood, kidneys, lungs, and, in the most serious cases, the brain.

Moreover, Neonatal lupus erythematosus (NLE) refers to a clinical spectrum of cutaneous, systemic abnormalities and cardiac, is found in newborn infants whose mothers have autoantibodies against Ro/SSA and La/SSB, is unusual and mostly self-limited but a few times may be related to serious sequelae. Therefore, careful monitoring of subsequent pregnancies with serial ultrasonography and echocardiography is essential.

Figure 2:  Lupus Market, by Type, 2022 & 2032 (USD Billion)

Source: Secondary Research, MRFR Database, Primary Research, and Analyst Review

Lupus Treatment Insights

The  lupus market segmentation, based on treatment, includes NSAIDS, corticosteroids, antimalarial drugs, biologics, and others. The antimalarial drugs segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period. Plaquenil and other antimalarials are the key way to control Lupus in the long term, and some lupus patients may be on Plaquenil for the rest of their lives. For the same reason, antimalarial drugs are a sort of “lupus life insurance.” 

However, NSAID medications relieve some lupus symptoms by lessening the inflammation responsible for the stiffness and uneasiness in joints, muscles, and other tissues. NSAIDs are comparatively mild than many other lupus drugs and may be taken either individually to treat a mild flare or in combination with other medications. At the same time, the biologics segment is projected to post the highest CAGR during the same period.

Lupus End-User Insights

The  lupus market data, based on end-users, include hospitals & clinics, diagnostic laboratories, and others. The hospital segment dominated the lupus market revenue during the forecast period. With hospitalization, treatment can help improve symptoms, prevent flares, and prevent any other health problem caused by Lupus. The treatment for this depends on the needs and symptoms of the type of health problem. 

However, diagnostic laboratories and others are expected to rise in forthcoming years since patients are supposed to Keep a record of symptoms when occurring and also keep a record of the duration of the symptoms. To keep records, doctors diagnose bodies for the proper treatment. Hence this segment is wholly connected and expected to rise during the study period.

Lupus Regional Insights

By region, the data provides market insights into North America, Asia-Pacific, Europe, and the Rest of the World. The North America Lupus market accounted for USD 3.3 billion in 2022, with a share of around 10.50%, and is projected to show a significant CAGR growth during the forecast period. This is attributed to the handiness of reimbursement and improved healthcare infrastructure, and availability of medication.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3:  LUPUS MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, MRFR Database, Primary Research, and Analyst Review

Europe’s lupus market accounts for the second-largest market share due to the increased prevalence of SLE in Europe. According to the Lupus Journal article, among the European countries, Sweden, Iceland, and Spain recorded the highest sales of SLE drugs. Moreover, the UK Lupus market held the largest market share, and the Germany Lupus market was the fastest-growing market in the region.

Asia Pacific Lupus Market is anticipated to rise at the fastest pace and contribute to an increased CAGR from 2022 to 2030. Asia-Pacific is expected to rise during the forecast period due to a number population and rising healthcare expenditure in this region. 

Additionally, the rising focus of major key players on technologies is propelling the market's growth rate in this region. Further, the China Lupus market held the largest market share, and the Indian lupus market was the fastest-growing market in the region.

Lupus Key Market Players & Competitive Insights

Major market players are using a lot of money on research and development activities to grow their business lines, which will assist the market to rise even more. Competitors are also making strategies to grow their footprints ly, with key market developments such as new product launches, mergers and acquisitions, contract-based agreements, high investments, and collaboration with other organizations. Participants in the lupus industry must provide cost-effective items to expand and capture the market in an increasingly competitive environment.

One of the primary business strategies adopted by manufacturers in the  Lupus industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, the Lupus industry has provided medicine with some of the most significant benefits. The Lupus market major player such as GlaxoSmithKline plc, F. Hoffmann-La Roche AG, and Cadila Healthcare.

In 2000, GlaxoSmithKline plc was established by a merger of SmithKline Beecham and Glaxo Wellcome, GSK plc (GSK) is a healthcare company that emphasizes developing, producing, and commercializing pharmaceuticals, consumer healthcare products, and vaccines. It provides drugs for treating diseases such as cancer, respiratory, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterial, dermatology, and a few rare diseases.

• Hoffmann-La Roche Ltd (Roche) is a company of biotechnology, developing drugs and diagnostics to treat diseases. This company provides medication for cancer, infectious diseases, other autoimmune diseases, CNS disorders, ophthalmological disorders, and respiratory diseases. It also provides tissue-based cancer diagnostics, diabetes management solutions, and in vitro diagnostics.

Key Companies in the Lupus market include

• Aurinia Pharmaceuticals Inc.


• Bristol-Myers Squibb Company


• Cadila Healthcare


• GlaxoSmithKline plc


• Mylan N.V.


• F. Hoffmann-La Roche AG


• Pfizer


• Inc

Lupus Industry Developments

November 2021 AstraZeneca, a U.K.-based biopharmaceutical company, made an announcement of positive results from its TULIP Phase 3 clinical trial program (focused on determining the efficacy and safety of Anifrolumab), stating that Saphnelo (anifrolumab) - a human monoclonal antibody presented greater reduction of SLE when used in combination with standard therapy than the use of only standard therapy.

In collaboration with GlaxoSmithKline, Benlysta is projected to lead (SLE) drug market sales in coming years because of its better safety profile as well as proven efficacy in clinical trials.

Lupus Market Segmentation

Lupus Type Outlook (USD Billion, 2018-2032)

• Systemic Lupus Erythematosus


• Neonatal Lupus


• Others

Lupus Treatment Outlook (USD Billion, 2018-2032)

• NSAIDS


• Corticosteroid


• Antimalarial Drug


• Biologics


• Other

Lupus End-User Outlook (USD Billion, 2018-2032)

• Hospital & Clinics


• Diagnostic Laboratories


• Others

Lupus Regional Outlook (USD Billion, 2018-2032)

• 
  

  North America

  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  

  Europe

  
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  

  Asia-Pacific

  
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America